Kameryn M Butler1, Cristina da Silva2, John J Alexander2, Madhuri Hegde1, Andrew Escayg3. 1. Department of Human Genetics, Emory University, Atlanta, Georgia. 2. Department of Human Genetics, Emory University, Atlanta, Georgia; EGL Genetics, Tucker, Georgia. 3. Department of Human Genetics, Emory University, Atlanta, Georgia. Electronic address: aescayg@emory.edu.
Abstract
BACKGROUND: The contribution of genetic factors to epilepsy has long been recognized and has been estimated to play a role in 70% to 80% of cases. Identification of a pathogenic variant can help families to better cope with the disorder, allows for genetic counseling to determine recurrence risk, and in some cases, can directly influence treatment options. In this study, we determined the diagnostic yield of a clinical gene panel applied to an unselected cohort of epilepsy patients. METHODS: Variant reports from 339 clinically referred epilepsy patients screened using a 110-gene panel were retrospectively reviewed. Variants were classified using the American College of Medical Genetics and Genomics guidelines. RESULTS: Pathogenic or likely pathogenic variants were identified in 62 individuals (18%) and potentially causative variants were identified in an additional 21 individuals (6%). Causative and potentially causative variants were most frequently identified in SCN1A (n = 15) and KCNQ2 (n = 10). Other genes in which disease-causing variants were identified in multiple individuals included CDKL5, SCN2A, SCN8A, SCN1B, STXBP1, TPP1, PCDH19, CACNA1A, GABRA1, GRIN2A, SLC2A1, and TSC2. Sixteen additional genes had variants identified in single individuals. CONCLUSIONS: We identified 87 variants in 30 different genes that could explain disease, of which 54% were not previously reported. This study confirms the utility of targeted gene panel analysis in epilepsy and highlights several factors to improve the yield of diagnostic genetic testing, including the critical need for clinical phenotype information and parental samples, microarray analysis for whole exon deletions and duplications, and frequent update of panels to incorporate new disease genes.
BACKGROUND: The contribution of genetic factors to epilepsy has long been recognized and has been estimated to play a role in 70% to 80% of cases. Identification of a pathogenic variant can help families to better cope with the disorder, allows for genetic counseling to determine recurrence risk, and in some cases, can directly influence treatment options. In this study, we determined the diagnostic yield of a clinical gene panel applied to an unselected cohort of epilepsypatients. METHODS: Variant reports from 339 clinically referred epilepsypatients screened using a 110-gene panel were retrospectively reviewed. Variants were classified using the American College of Medical Genetics and Genomics guidelines. RESULTS: Pathogenic or likely pathogenic variants were identified in 62 individuals (18%) and potentially causative variants were identified in an additional 21 individuals (6%). Causative and potentially causative variants were most frequently identified in SCN1A (n = 15) and KCNQ2 (n = 10). Other genes in which disease-causing variants were identified in multiple individuals included CDKL5, SCN2A, SCN8A, SCN1B, STXBP1, TPP1, PCDH19, CACNA1A, GABRA1, GRIN2A, SLC2A1, and TSC2. Sixteen additional genes had variants identified in single individuals. CONCLUSIONS: We identified 87 variants in 30 different genes that could explain disease, of which 54% were not previously reported. This study confirms the utility of targeted gene panel analysis in epilepsy and highlights several factors to improve the yield of diagnostic genetic testing, including the critical need for clinical phenotype information and parental samples, microarray analysis for whole exon deletions and duplications, and frequent update of panels to incorporate new disease genes.
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: Andrew S Allen; Samuel F Berkovic; Patrick Cossette; Norman Delanty; Dennis Dlugos; Evan E Eichler; Michael P Epstein; Tracy Glauser; David B Goldstein; Yujun Han; Erin L Heinzen; Yuki Hitomi; Katherine B Howell; Michael R Johnson; Ruben Kuzniecky; Daniel H Lowenstein; Yi-Fan Lu; Maura R Z Madou; Anthony G Marson; Heather C Mefford; Sahar Esmaeeli Nieh; Terence J O'Brien; Ruth Ottman; Slavé Petrovski; Annapurna Poduri; Elizabeth K Ruzzo; Ingrid E Scheffer; Elliott H Sherr; Christopher J Yuskaitis; Bassel Abou-Khalil; Brian K Alldredge; Jocelyn F Bautista; Samuel F Berkovic; Alex Boro; Gregory D Cascino; Damian Consalvo; Patricia Crumrine; Orrin Devinsky; Dennis Dlugos; Michael P Epstein; Miguel Fiol; Nathan B Fountain; Jacqueline French; Daniel Friedman; Eric B Geller; Tracy Glauser; Simon Glynn; Sheryl R Haut; Jean Hayward; Sandra L Helmers; Sucheta Joshi; Andres Kanner; Heidi E Kirsch; Robert C Knowlton; Eric H Kossoff; Rachel Kuperman; Ruben Kuzniecky; Daniel H Lowenstein; Shannon M McGuire; Paul V Motika; Edward J Novotny; Ruth Ottman; Juliann M Paolicchi; Jack M Parent; Kristen Park; Annapurna Poduri; Ingrid E Scheffer; Renée A Shellhaas; Elliott H Sherr; Jerry J Shih; Rani Singh; Joseph Sirven; Michael C Smith; Joseph Sullivan; Liu Lin Thio; Anu Venkat; Eileen P G Vining; Gretchen K Von Allmen; Judith L Weisenberg; Peter Widdess-Walsh; Melodie R Winawer Journal: Nature Date: 2013-08-11 Impact factor: 49.962
Authors: Tyler Mark Pierson; Hongjie Yuan; Eric D Marsh; Karin Fuentes-Fajardo; David R Adams; Thomas Markello; Gretchen Golas; Dimitre R Simeonov; Conisha Holloman; Anel Tankovic; Manish M Karamchandani; John M Schreiber; James C Mullikin; Cynthia J Tifft; Camilo Toro; Cornelius F Boerkoel; Stephen F Traynelis; William A Gahl Journal: Ann Clin Transl Neurol Date: 2014-03-01 Impact factor: 4.511
Authors: Ragna S Boerma; Kees P Braun; Marcel P H van den Broek; Maarten P H van de Broek; Frederique M C van Berkestijn; Marielle E Swinkels; Eveline O Hagebeuk; Dick Lindhout; Marjan van Kempen; Maartje Boon; Joost Nicolai; Carolien G de Kovel; Eva H Brilstra; Bobby P C Koeleman Journal: Neurotherapeutics Date: 2016-01 Impact factor: 7.620
Authors: Andrea Merseburg; Jacquelin Kasemir; Eric W Buss; Felix Leroy; Tobias Bock; Alessandro Porro; Anastasia Barnett; Simon E Tröder; Birgit Engeland; Malte Stockebrand; Anna Moroni; Steven A Siegelbaum; Dirk Isbrandt; Bina Santoro Journal: Elife Date: 2022-08-16 Impact factor: 8.713
Authors: Dina Simkin; Christina Ambrosi; Kelly A Marshall; Luis A Williams; Jordyn Eisenberg; Mennat Gharib; Graham T Dempsey; Alfred L George; Owen B McManus; Evangelos Kiskinis Journal: Trends Pharmacol Sci Date: 2022-05 Impact factor: 17.638
Authors: Patrick J Mulcahey; Sheng Tang; Hajime Takano; Alicia White; Dayana R Davila Portillo; Owen M Kane; Eric D Marsh; Zhaolan Zhou; Douglas A Coulter Journal: Exp Neurol Date: 2020-06-22 Impact factor: 5.620